Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model

Jun Ho Park, Ming Zhao, Qinghong Han, Yu Sun, Takashi Higuchi, Norihiko Sugisawa, Jun Yamamoto, Shree Ram Singh, Bryan Clary, Michael Bouvet, Robert M. Hoffman

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a colon cancer primary tumor using a patient-derived orthotopic xenograft (PDOX) nude mouse model. Forty colon cancer primary tumor PDOX mouse models were divided into 4 groups of 10 mice each (total 40 mice) by measuring the tumor size. The groups were as follows: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, N = 10 mice) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, N = 10 mice); o-rMETase (100 units/day, oral 14 consecutive days, N = 10 mice); combination of 5-FU + OXA and o-rMETase (N = 10 mice). All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FU + OXA and o-rMETase was significantly more efficacious than other treatments. The present study demonstrates the efficacy of o-rMETase combination therapy on a PDOX colon cancer primary tumor, suggesting potential clinical development of o-rMETase in recalcitrant cancer.

Original languageEnglish
Pages (from-to)306-310
Number of pages5
JournalBiochemical and biophysical research communications
Volume518
Issue number2
DOIs
Publication statusPublished - 2019 Oct 15
Externally publishedYes

Keywords

  • Colon cancer
  • Methioninase
  • Patient-derived orthotopic xenograft
  • Primary tumor
  • Red fluorescent protein

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model'. Together they form a unique fingerprint.

Cite this